Uses of IL-23 agonists and antagonists; related reagents

Details for Australian Patent Application No. 2004219625 (hide)

International Classifications

Event Publications

29 September 2005 PCT application entered the National Phase

PCT publication WO2004/081190 Priority application(s): WO2004/081190

19 August 2010 Application Accepted

Published as AU-B-2004219625

16 December 2010 Standard Patent Sealed

11 October 2012 Application for Amendment

The nature of the amendment is: Amend the Patentee to read Merck Sharp & Dohme Corp. . Address for service in Australia - Griffith Hack Level 29, Northpoint 100 Miller Street North Sydney NSW 2060 2004233334 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo- [1,5-c]-pyrimidine adenosine A2a receptor antagonists Schering Corporation The nature of the amendment is: Amend the Patentee to read Merck Sharp & Dohme Corp. . Address for service in Australia - Griffith Hack Level 29, Northpoint 100 Miller Stre

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.